About Serum paraoxonase/lactonase 3
Serum paraoxonase/lactonase 3 (PON3) is a protein
from Homo sapiens identified by UniProt accession
Q15166, 354 residues long.
MolForge cross-references it against 0 known binders and
160 disease associations.
Target properties
| Protein name | Serum paraoxonase/lactonase 3 |
| UniProt accession | Q15166 |
| Gene | PON3 |
| Organism | Homo sapiens |
| Length | 354 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (160)
Diseases linked to this target (Open Targets).
- amyotrophic lateral sclerosis · score 0.37
- Amyotrophic lateral sclerosis · score 0.37
- blood protein measurement · score 0.33
- high density lipoprotein cholesterol measurement · score 0.24
- head and neck squamous cell carcinoma · score 0.11
- neoplasm · score 0.09
- hepatocellular carcinoma · score 0.09
- hypertriglyceridemia 2 · score 0.06
- cholesterol-ester transfer protein deficiency · score 0.05
- neonatal intrahepatic cholestasis due to citrin deficiency · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15166-F1 | alphafold | PREDICTED | 96.32 | — |
Amino-acid sequence (354 residues)
MGKLVALVLL GVGLSLVGEM FLAFRERVNA SREVEPVEPE NCHLIEELES GSEDIDILPS GLAFISSGLK YPGMPNFAPD EPGKIFLMDL NEQNPRAQAL EISGGFDKEL FNPHGISIFI DKDNTVYLYV VNHPHMKSTV EIFKFEEQQR SLVYLKTIKH ELLKSVNDIV VLGPEQFYAT RDHYFTNSLL SFFEMILDLR WTYVLFYSPR EVKVVAKGFC SANGITVSAD QKYVYVADVA AKNIHIMEKH DNWDLTQLKV IQLGTLVDNL TVDPATGDIL AGCHPNPMKL LNYNPEDPPG SEVLRIQNVL SEKPRVSTVY ANNGSVLQGT SVASVYHGKI LIGTVFHKTL YCEL
Explore Serum paraoxonase/lactonase 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets